LX-2343

Research use only, not for human use.

LX-2343 is an non-ATP competitive PI3K inhibitor that negatively regulates AKT/mTOR signaling.

LX-2343 is an non-ATP competitive PI3K inhibitor that negatively regulates AKT/mTOR signaling, thus promoting autophagy and increasing Aβ clearance, also inhibits BACE1 enzymatic activity with IC50 of 11.43 uM; reduced Aβ production involving JNK/APPThr668 pathway inhibition, LX2343 (5-20 uM) dose-dependently decreases Aβ accumulation in HEK293-APPsw and CHO-APP cells, and promotes Aβ clearance in SH-SY5Y cells and primary astrocytes; significantly ameliorates cognitive deficits and markedly ameliorates the Aβ pathology in brains in APP/PS1 transgenic mice.

LX2343

PI3K/Akt/mTOR signaling

PI3K

BACE1

Neurological Disease

——

333745-53-2

474.91

C22H19ClN2O6S

>98% (HPLC)

< 1 mg/ml refers to the product slightly soluble or insoluble

C1=C(NC(CN(C2=CC(Cl)=CC=C2OC)S(C2=CC=CC=C2)(=O)=O)=O)C=C2OCOC2=C1

N-(1,3-benzodioxol-5-yl)-2-[5-chloro-2-methoxy(phenylsulfonyl)anilino]acetamide

(-20℃)

With Ice Pack

≥ 2 years